瑞士Apotech  www.apotech.ch  www.enzo.com
瑞士Apotech成立于2000年.
 

Apotech® - A Brand of Enzo Life Sciences, Inc.

Highest Standards for Research Kits™.
APOTECH Corporation was founded in 2000 in Geneva, Switzerland. The company is a globally operating life science reagents company discovering, developing and producing innovative research kits and sets in the field of apoptosis, immunology and inflammation. A comprehensive product offering, combined with outstanding technical information supports researchers in the advancement of their science.

Apotech Corporation is the operational headquarters of Apotech®, an internationally recognized brand acknowledged as a leader in producing high quality recombinant proteins and antibodies in key research areas. The successful Apotech® brand of innovative research kits and sets covers the fields of Apoptosis, Cancer Research, Immunology, Neuroscience, Signal Transduction and Oxidative Stress. Selected kits with high potential for human diagnostics applications are outlicensed to specialized companies in the field.

On April 29, 2005 AXXORA Life Sciences Inc. and APOTECH Corporation announced the merger of the two companies. Following this merger the companies continued operating from their respective headquarters in San Diego, CA, USA and Epalinges, Switzerland, and under their current management teams.

The merger has resulted in APOTECH Corporation operating as a new business division of AXXORA Life Sciences Inc., and a member of the AXXORA Platform (www.axxora.com). APOTECH’s cutting edge product line and know-how in recombinant proteins, antibodies and ELISA kits strengthens the group as a manufacturer and single-source supplier of over 14,000 life science reagents and research kits to researchers worldwide.

Prior to the transaction the two companies had a longstanding successful business relationship through distribution and co-development agreements. The merger has strengthened the company’s ability to provide its customers with superior service, innovative products, and enhanced production capabilities.